The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

(2016) Gaik W. Tew et al.   GASTROENTEROLOGY

Complications of biologics in inflammatory bowel disease

(2015) Paula Sousa et al.   CURRENT OPINION IN GASTROENTEROLOGY

Integrins and adhesion molecules as targets to treat inflammatory bowel disease

(2015) Ivana Bravatà et al.   CURRENT OPINION IN PHARMACOLOGY

Biological Agents for Moderately to Severely Active Ulcerative Colitis

(2014) Silvio Danese et al.   ANNALS OF INTERNAL MEDICINE

Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases

(2014) Silvio Danese et al.   GASTROENTEROLOGY

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease – an update

(2013) Monica Cesarini et al.   Expert Review of Clinical Immunology

Etrolizumab: Anti-β7—A Novel Therapy for Ulcerative Colitis

(2013) Kirk K. Lin et al.   GASTROENTEROLOGY

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

(2012) Paul J Rutgeerts et al.   GUT

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy

(2011) S. Danese et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

(2011) EG Stefanich et al.   BRITISH JOURNAL OF PHARMACOLOGY

Ulcerative Colitis

(2011) Silvio Danese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis

(2011) Saskia Thomas et al.   INFLAMMOPHARMACOLOGY

Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease

(2010) Gionata Fiorino et al.   Expert Review of Clinical Immunology

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Integrins

(2009) Malgorzata Barczyk et al.   CELL AND TISSUE RESEARCH